Cara Therapeutics announced a strategic reprioritization plan, terminating their Phase 3 clinical program for oral difelikefalin in chronic kidney disease and reducing their workforce, resulting in expected charges of $2.5-3 million in Q1 2024. They also announced the departure of their Chief Scientific Officer.